iCURE
Business Services · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
15332 73rd Ave Apt 1E, Flushing, New Yor...Phone Number
(651) 404-7373Website
www.myicure.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About iCURE
iCURE specializes in revenue cycle management optimization and integrated business support for private medical practices across the U.S. Their services include electronic medical records, billing services, patient payment management, document management, and compliance solutions. With a focus on maximizing revenue potential and streamlining operations, iCURE aims to help practices thrive by reducing expenses and increasing efficiency. They are part of a nationwide network of over 1,500 offices, providing comprehensive support tailored to the unique needs of each practice.Explore more
iCURE Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is iCURE your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
iCURE, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on iCURE recently announced quarterly report
Product Launch: Get notified when iCURE launches new products
Check if iCURE has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if iCURE had a recent Job posting/layoffs
Check out if iCURE is spiking on competitors!
Funding: Get notified immidiatlly once iCURE has new funding data
Congratulate Masked Content for being promoted to Masked Content at iCURE
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to iCURE
Compare insights from companies similar to iCURE, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
iCURE is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
iCURE is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about iCURE.
iCURE Tech Stack
A closer look at the technologies used by iCURE
See more technologies
iCURE News & Media
Icure obtient une autorisation de mise sur le marché pour le premier patch de donépézil au monde, destiné au traitement de la démence de type Alzheimer en Corée
SÉOUL, Corée du Sud--(BUSINESS WIRE)--Icure Pharmaceutical Inc. (KOSDAQ : 175250), société biopharmaceutique basée en Corée, a annoncé aujourd’hui que son patch de donépézil, pour le traitement de la démence de type Alzheimer, avait obtenu une autorisation de mise sur le marché, de la part du ministère coréen de la Sécurité des aliments et des médicaments. La procédure d’autorisation de mise sur le marché a duré 7 mois à compter du dépôt de la demande enIcure ottiene l’approvazione del primo cerotto al mondo a base di donepezil quale prodotto farmaceutico per il trattamento della demenza di tipo Alzheimer in Corea
SEUL, Corea del Sud--(BUSINESS WIRE)--Icure Pharmaceutical Inc. (KOSDAQ: 175250), un’azienda biofarmaceutica coreana, ha annunciato oggi di aver ottenuto l’approvazione del suo cerotto a base di donepezil quale terapia per il trattamento della demenza di tipo Alzheimer da parte del Ministero per la sicurezza degli alimenti e dei farmaci della Corea. Il processo di approvazione del prodotto farmaceutico si è concluso a 7 mesi di distanza dalla presentazione della domanda nell’aprile del 2021. TrICURE、アルツハイマー型認知症治療のドネペジルパップ剤が世界初で品目許可の承認を獲得
韓国ソウル--(BUSINESS WIRE)--（ビジネスワイヤ） -- 韓国の製薬会社ICURE (KOSDAQ: 175250)は、開発したアルツハイマー型認知症治療剤ドネペジル（Donepezil）パップ剤が 韓国食品医薬安全処から正式品目許可の承認を獲得したことを発表した。ドネペジルパップ剤の品目許可の承認は今年4月の申請以来約7か月ぶりである。ICUREは今回の承認により世界で初めてドネペジルパップ剤の商用化に成功したことになる。 ドネペジルは、現在FDAの承認を受けたアルツハイマー治療剤の中で、最も長期間にわたり軽症から重症度及び重症認知症患者にまで幅広く処方されている代表的な治療剤である。これまでドネペジルは剤型の開発が難しく経口用だけ商用化されてきた。ICUREが世界で初めて臨床第3相試験に成功し、ドネペジルパップ剤により、既存のドネペジル経口剤を1日1回服用することから1週間に2回パップ剤を付着することに改善され、服用の便宜性を高めてアルツハイマー型認知症患者及び介護者たちの生活を大きく改善できると期待されている。 ICUREは韓国、台湾、オーストラリア、マレーシア
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding iCURE
Sign Up For FreeTo access detailed company insights
iCURE specializes in revenue cycle management optimization and integrated business support for private medical practices across the U.S. Their services include electronic medical records, billing services, patient payment management, document management, and compliance solutions. With a focus on maximizing revenue potential and streamlining operati... Read More
